Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02255032) enrolled 22 people in total — 17 received a higher dose (4 mg) of a treatment called CLS-TA, and 5 received a lower dose (0.8 mg). All 22 participants completed the trial with no drop-outs. The trial was looking at swelling at the back of the eye (a condition called macular oedema) in people with uveitis, an inflammatory eye condition. Specifically, it measured the thickness of a central area at the back of the eye — called the central subfield — using a scanning technology that produces detailed images of the eye's layers. The reported data shows that the main thing being tracked was how much that central eye thickness changed between the start of the trial and after treatment, measured in microns (a micron is one-thousandth of a millimetre). In the group receiving the higher 4 mg dose, the average thickness decreased by approximately 164 microns from their starting measurement. In the group receiving the lower 0.8 mg dose, the average thickness decreased by approximately 78 microns from their starting measurement. No other outcome measures were included in the submitted results data. It is worth noting that this was a small trial, and the two groups had very different numbers of participants (17 versus 5), which the reported data does not explain further. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with uveitis (inflammation inside the eye) that is not caused by an infection.
- You have been diagnosed with swelling in the central part of your retina (called macular edema) that is related to your non-infectious uveitis.
Who may not be able to join:
- You have had an injury to your eye in the last 6 months.
- You have had laser treatment or freezing treatment on your eye in the last 6 months.
- You have had an injection into your eye to treat abnormal blood vessel growth (anti-VEGF injection) in the last 2 months.
- You have another eye condition, apart from uveitis and macular edema, that affects your central vision.
- You have previously had a specific type of steroid injection (triamcinolone acetonide) delivered into the space behind your eye wall (called a suprachoroidal injection) in the eye being studied.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following Uveitis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.